CRESTOR Athero Imaging Head to Head IVUS Study (SATURN)

This study has been completed.
Sponsor:
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00620542
First received: February 6, 2008
Last updated: July 11, 2012
Last verified: July 2012
  Purpose

A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.


Condition Intervention Phase
Coronary Atherosclerosis
Drug: Rosuvastatin
Drug: Atorvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]

    Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:

    [sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.



Secondary Outcome Measures:
  • Numbers of Patients Showing Regression in PAV [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Regression defined as a change from baseline in PAV < 0

  • Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV) [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.

  • Numbers of Patients Showing Regression in TAV [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Regression defined as a change from baseline in TAV < 0

  • Total Cholesterol Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • LDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Triglycerides Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Non-HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • LDL-C/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Total Cholesterol/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Non-HDL-C/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apolipoprotein B Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apolipoprotein A-1 Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apoliprotein B/Apolipoprotein A-1 Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • VLDL-C During the 104 Week Treatment Period [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.


Enrollment: 2333
Study Start Date: January 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin 20 mg
Rosuvastatin 20 mg distributed in 2-week run-in period
Drug: Rosuvastatin
capsule, oral, once daily
Other Name: Crestor
Active Comparator: Atorvastatin 40 mg
Atorvastatin 40 mg distributed in 2-week run-in period
Drug: Atorvastatin
capsule, oral, one daily
Other Name: Lipitor
Experimental: Rosuvastatin 40 mg
Rosuvastatin 40 mg distributed in core 2-year study
Drug: Rosuvastatin
capsule, oral, once daily
Other Name: Crestor
Active Comparator: Atorvastatin 80 mg
Atorvastatin 80 mg distributed in core 2-year study
Drug: Atorvastatin
capsule, oral, one daily
Other Name: Lipitor

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical indication for coronary angiography
  • Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has >20% reduction in lumen diameter by visual estimation
  • Left main coronary artery must have <=50% reduction in lumen diameter by visual estimation
  • LDL-C >100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C >80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks

Exclusion Criteria:

  • Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.
  • Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).
  • Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620542

  Show 195 Study Locations
Sponsors and Collaborators
AstraZeneca
The Cleveland Clinic
Investigators
Principal Investigator: Stephen J Nicholls, MBBS, PhD Cleveland Clinic Foundation, Cardiovascular Medicine
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00620542     History of Changes
Other Study ID Numbers: D356IC00001, 2007-004000-13
Study First Received: February 6, 2008
Results First Received: May 22, 2012
Last Updated: July 11, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Belgium: Ministry of Social Affairs, Public Health and the Environment
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: Ministry of Health
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Spain: Spanish Agency of Medicines
United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Coronary artery disease

Additional relevant MeSH terms:
Atherosclerosis
Coronary Artery Disease
Myocardial Ischemia
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Atorvastatin
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 22, 2014